Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

118.61
+3.322.88%
Post-market: 118.610.00000.00%19:14 EDT
Volume:1.21M
Turnover:142.19M
Market Cap:17.36B
PE:10.61
High:118.77
Open:115.02
Low:114.66
Close:115.29
Loading ...

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2025-03-07

Reuters
·
08 Mar

SLDB Stock Rallies 60% in a Month: Here's What You Should Know

Zacks
·
07 Mar

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
07 Mar

Biogen (BIIB) Receives a Hold from Bernstein

TIPRANKS
·
06 Mar

Do You Own 15 Stocks Morningstar Calls The Top 'Wealth Destroyers?'

Blockhead
·
03 Mar

Biogen's Alzheimer's Treatment Lecanemab Denied Approval in Australia

MT Newswires Live
·
03 Mar

3 Reasons BIIB is Risky and 1 Stock to Buy Instead

StockStory
·
03 Mar

As baby boomers turn 80, there aren't enough doctors to treat 'emergency levels' of dementia patients

Dow Jones
·
01 Mar

Pfizer quietly made some big DEI changes

Quartz
·
01 Mar

Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug

Dow Jones
·
28 Feb

Biogen, Eisai Say EMA Panel Reaffirms Positive Opinion on Lecanemab

MT Newswires Live
·
28 Feb

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

PR Newswire
·
28 Feb

Biogen, Eisai announces CHMP of EMA reaffirmed positive opinion of lecanemab

TIPRANKS
·
28 Feb

EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug

Reuters
·
28 Feb

EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug

Reuters
·
28 Feb

BRIEF-EMA's CHMP Says Opinion Recommending Marketing Authorisation For Leqembi Not Need To Be Updated

Reuters
·
28 Feb

Ema Says Chmp: Concluded That Its Opinion Recommending Marketing Authorisation for Leqembi (Lecanemab) Does Not Need to Be Updated

THOMSON REUTERS
·
28 Feb

Indivior Parts Ways With CEO as Leadership Shakeup Continues

Dow Jones
·
27 Feb

Biogen Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
27 Feb

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
26 Feb